Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.
Wang Y, Wang G, Xiang W, Liu X, Jiang M, Hu J.
Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2024.176558 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för GW843682X. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarComprehensive Analysis of the Expression, Prognostic Value, and Immune Infiltration Activities of GABRD in Colon Adenocarcinoma.
Huang F, Wang Z, Zhu L, Lin C, Wang JX.
Mediators Inflamm · research-article; journal article · DOI 10.1155/2023/8709458Fatty acid metabolism is related to the immune microenvironment changes of gastric cancer and RGS2 is a new tumor biomarker.
Yang S, Sun B, Li W, Yang H, Li N, Zhang X.
Front Immunol · research-article; journal article · DOI 10.3389/fimmu.2022.1065927The cytotoxic effect of GW843682X on nasopharyngeal carcinoma.
Hu Q, Chu Y, Hu W, Peng M, Song Q.
Anticancer Agents Med Chem · journal article · DOI 10.2174/1871520616666160520112451Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment.
Liu X.
Transl Oncol · review-article; review; journal article · DOI 10.1016/j.tranon.2015.03.010Polo-like kinase 1 (PLK1) is involved in toll-like receptor (TLR)-mediated TNF-α production in monocytic THP-1 cells.
Hu J, Wang G, Liu X, Zhou L, Jiang M, Yang L.
PLoS One · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pone.0078832In vitro targeting of Polo-like kinase 1 in bladder carcinoma: comparative effects of four potent inhibitors.
Brassesco MS, Pezuk JA, Morales AG, de Oliveira JC, Roberto GM, da Silva GN, Francisco de Oliveira H, Scrideli CA, Tone LG.
Cancer Biol Ther · research support, non-u.s. gov't; research-article; journal article · DOI 10.4161/cbt.25087An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
Spaniol K, Boos J, Lanvers-Kaminsky C.
Anticancer Drugs · research support, non-u.s. gov't; journal article · DOI 10.1097/cad.0b013e3283454526Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.
Cell Cycle · research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.4161/cc.10.8.15353Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA.
Cell Cycle · research support, non-u.s. gov't; journal article · DOI 10.4161/cc.10.8.15342A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.
Leukemia · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1038/leu.2009.94Evaluation of Polo-like Kinase 1 inhibition on the G2/M checkpoint in Acute Myelocytic Leukaemia.
Didier C, Cavelier C, Quaranta M, Demur C, Ducommun B.
Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2008.06.062In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA, Cheung M.
Mol Cancer Ther · journal article · DOI 10.1158/1535-7163.mct-06-0543